Chick-fil-A Inc., an American restaurant chain specializing in chicken sandwiches, announced it will no longer serve chicken that is antibiotic-free. This decision reversed the brand's long-time pledge of "No Antibiotics Ever."
Why Chick-fil-A Changed Its Stance
According to Associated Press News, Chick-fil-A's move was prompted by the predicted supply shortage. This is also a sudden change of heart from its vow not to use chicken fed with antibiotics.
For years, Chick-fil-A has committed to serving only antibiotic-free chickens. The chain explained that this pledge is intended to help prevent human antibiotic resistance related to the widespread use of the drugs in most livestock production.
A Shift to Standard NAIHM
The restaurant announced it would now embrace a standard called the "no antibiotics important to human medicine" (NAIHM), which means it would allow some antibiotics. The NAIHM involves steering clear of certain medications that are commonly used for the treatment of humans and restricting the usage of animal antibiotics to particular instances of animal illness.
Chick-fil-A shared that it will apply the new NAIHM policy starting this spring. Through its spokesperson, the company said this move mirrors its concerns about its capability to obtain enough supplies of antibiotic-free chicken.
"To maintain supply of the high-quality chicken you expect from us, Chick-fil-A will shift from No Antibiotics Ever (NAE) to No Antibiotics Important To Human Medicine (NAIHM) starting in the Spring of 2024," Chick-fil-A said in a statement.
The fast-food chain added, "NAE means no antibiotics of any kind were used in raising the animal. NAIHM restricts the use of those antibiotics that are important to human medicine and commonly used to treat people, and allows the use of animal antibiotics only if the animal and those around it were to become sick."
Photo by: Malhar Patel/Unsplash


Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
OpenAI Explores Massive Funding Round at $750 Billion Valuation
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 



